Figure 4.
Treg suppression assay from fluorescent activated cell sorting purified Treg cells in CD3G-mutated patients. (A) CD25hiCD127lo Treg sort purification strategy from control (left) and patient (right) samples. Intranuclear FOXP3 staining was performed on CD25loCD127hi Teff cells (solid blue) and CD25hiCD127lo Treg cells (red line). (B) Representative plots of Cell Trace Violet dilution in experiments in which CD4+ CD25low CD127hi Teff cells from controls were either left unstimulated (solid blue) or stimulated with anti-CD3 + anti-CD28 + anti-CD2, in the absence (solid gray) or presence (red line) of Treg cells from controls (left) or from CD3G-mutated patients (right). (C) Cumulative percentage of dividing cells in Treg suppression assay, normalized to the no Treg group within each individual experiment. Treg function was tested in 4 patients (P2-P5) and 4 controls. Results are expressed as mean ± standard deviation. *P < .05; **P < .01; ***P < .001.